» Articles » PMID: 36441359

Significance of C-reactive Protein in Patients with Chronic Myelomonocytic Leukemia

Overview
Specialty General Medicine
Date 2022 Nov 28
PMID 36441359
Authors
Affiliations
Soon will be listed here.
Abstract

In a retrospective study, we analyzed the prevalence of elevated C‑reactive protein (CRP) serum levels in 148 patients with chronic myelomonocytic leukemia (CMML), their potential prognostic impact, and potential correlations with laboratory features. Normal, up to 10-fold, and more than 10-fold elevated CRP levels were found in 18%, 59%, and 23% of CMML patients, respectively. Using the CRP cutoff value of 10 mg/L of the widely used Glasgow score, high CRP values were associated with inferior survival (13 vs. 39 months, p = 0.014), which retained prognostic significance in multivariate analysis. High CRP values were associated with lower hemoglobin levels. The survival difference between patients with normal (< 5 mg/L) and elevated CRP levels persisted after exclusion of patients with clinical infection. These findings indicate that in CMML patients, the presence of an acute-phase reaction is associated with a poor outcome, independent of clinical infection.

Citing Articles

Prognostic value of Glasgow prognostic score in hematological malignancies: a systematic review and meta-analysis.

Jiang L, Jin W Int J Hematol. 2025; .

PMID: 39899232 DOI: 10.1007/s12185-025-03935-z.


Prognostic significance of C-reactive protein in patients with cervical cancer: a meta-analysis.

Yang S, Zhang Z, Shen L Front Oncol. 2023; 13:1232409.

PMID: 37731642 PMC: 10507700. DOI: 10.3389/fonc.2023.1232409.

References
1.
Itzykson R, Solary E . An evolutionary perspective on chronic myelomonocytic leukemia. Leukemia. 2013; 27(7):1441-50. DOI: 10.1038/leu.2013.100. View

2.
Germing U, Strupp C, Aivado M, Gattermann N . New prognostic parameters for chronic myelomonocytic leukemia. Blood. 2002; 100(2):731-2; author reply 732-3. DOI: 10.1182/blood-2002-01-0330. View

3.
Proctor M, Morrison D, Talwar D, Balmer S, OReilly D, Foulis A . An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer. 2011; 104(4):726-34. PMC: 3049591. DOI: 10.1038/sj.bjc.6606087. View

4.
Hasselbalch H . Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?. Blood. 2012; 119(14):3219-25. DOI: 10.1182/blood-2011-11-394775. View

5.
Elena C, Galli A, Such E, Meggendorfer M, Germing U, Rizzo E . Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016; 128(10):1408-17. PMC: 5036538. DOI: 10.1182/blood-2016-05-714030. View